AMPs clear bacterial infection through various mechanisms: disrupting the bacterial outer membrane, inducing reactive oxygen species (ROS) production, or interfering with bacterial metabolism.[13] Due to the multiplexed mechanisms, AMPs are potentially advantageous against the MDR.[14, 15] However, AMPs are metabolically unstable and exhibit potential toxic side effects such as high haemolytic activity hindering clinical development.[16, 17, 18, 19]. The gene discussed is ADSL; the disease is bacterial infectious disease.